KR20170135485A - Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component - Google Patents
Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component Download PDFInfo
- Publication number
- KR20170135485A KR20170135485A KR1020160067484A KR20160067484A KR20170135485A KR 20170135485 A KR20170135485 A KR 20170135485A KR 1020160067484 A KR1020160067484 A KR 1020160067484A KR 20160067484 A KR20160067484 A KR 20160067484A KR 20170135485 A KR20170135485 A KR 20170135485A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- melanin
- composition
- white
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 230000002087 whitening effect Effects 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 57
- 241001664021 Cynanchum ascyrifolium Species 0.000 title abstract description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 18
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 18
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 208000003351 Melanosis Diseases 0.000 claims description 12
- 239000000049 pigment Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- -1 foundation Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 206010014970 Ephelides Diseases 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 208000000069 hyperpigmentation Diseases 0.000 claims description 8
- 230000003810 hyperpigmentation Effects 0.000 claims description 8
- 208000021710 Hyperpigmentation disease Diseases 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 206010008570 Chloasma Diseases 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000012641 Pigmentation disease Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 abstract description 16
- 229960000271 arbutin Drugs 0.000 abstract description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 208000031019 skin pigmentation disease Diseases 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 20
- 238000009472 formulation Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 210000002752 melanocyte Anatomy 0.000 description 8
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 7
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940111760 white rice extract Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- XHSWVNQODRKABJ-UHFFFAOYSA-N 2,7-dinitroindazole Chemical compound [O-][N+](=O)C1=CC=CC2=CN([N+]([O-])=O)N=C12 XHSWVNQODRKABJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000032989 Ipomoea lacunosa Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- OMUOMODZGKSORV-UVTDQMKNSA-N aurone Chemical compound O1C2=CC=CC=C2C(=O)\C1=C\C1=CC=CC=C1 OMUOMODZGKSORV-UVTDQMKNSA-N 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- XDEURYRPQDIBSL-UHFFFAOYSA-N dopaminechrome (keto form) Chemical compound O=C1C(=O)C=C2CCNC2=C1 XDEURYRPQDIBSL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- FXURFKFOPCZEKG-UHFFFAOYSA-N indole-5,6-quinone-2-carboxylic acid Chemical compound O=C1C(=O)C=C2NC(C(=O)O)=CC2=C1 FXURFKFOPCZEKG-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-YIILYMKVSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)C(OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-YIILYMKVSA-N 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000011845 white flour Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 백전 추출물을 유효성분으로 함유하는 피부 미백용 조성물에 관한 것이다.The present invention relates to a composition for whitening skin, which comprises a white flake extract as an active ingredient.
멜라닌은 머리카락 및 피부의 색상을 결정하는 주요 인자이며, 자외선으로부터 피부세포를 보호하는 역할을 한다. 그러나 과도한 멜라닌의 축적은 주근깨 및 기미와 같은 과다 색소 침착 현상을 유발한다. 표피층의 기저층(basal layer)에 존재하는 멜라닌 형성 세포는 멜라노솜이라고 불리는 특정한 구조를 가지고 있으며, 이곳에서 멜라닌형성 효소(melanogenic enzyme)의 작용으로 멜라닌이 만들어진다. 멜라닌은 검은색 및 갈색계열의 유멜라닌(eumelanin)과 노란색 및 붉은계열의 페오멜라닌(pheomelanin)이 있으며, 멜라닌의 합성은 티로시나아제(tyrosinase)에 의해 티로신(tyrosine)이 도파(DOPA) 및 도파 퀴논(DOPA quinone)으로 전환되면서 시작된다. 또한, TRP-2(tyrosinase-related protein 2)는 도파 크롬(DOPA chrome)을 5,6-디히드록시인돌-2-카복실산(5,6-dihydroxyindole-2-carboxylic acid)으로, TRP-1(tyrosinase-related protein 1)은 인돌-5,6-퀴논-2-카복실산(indole-5,6-quinone-2-carboxylic acid)으로 산화반응을 촉매하며, 유멜라닌(eumelanin) 합성에 티로시나아제(tyrosinase)와 TRP-1 및 2가 관여하고 있다. 또한, 멜라닌 형성의 조절인자로 잘 알려진 MITF(microphthalmia-associated transcription factor)는 나선-고리-나선-루신 지퍼(helix-loop-helix-leucine zipper) 구조를 가진 전사인자(transcription factor)로서 멜라닌 형성을 통해 흑화과정과 세포의 증식 및 생존을 조절하는 것으로 잘 알려져 있다. 멜라닌 생합성에 관여하는 인자로는 α-MSH(α-melanocyte stimulating hormone), 부신피질자극호르몬(adrenocorticotropic hormone), PGE2(prostaglandine E2) 등이 있으며, cAMP를 통해 멜라닌 합성을 조절하는 것으로 보고되어 있다.Melanin is a key determinant of hair and skin color, and it protects skin cells from ultraviolet light. However, excessive accumulation of melanin causes hyperpigmentation such as freckles and spots. The melanin-forming cells in the basal layer of the epidermis have a specific structure called melanosomes, in which melanin is produced by the action of a melanogenic enzyme. Melanin has black and brown series of eumelanin and yellow and red series of pheomelanin. The synthesis of melanin is caused by tyrosinase, tyrosine is doped (DOPA) and dopa It begins with conversion to quinone (DOPA quinone). In addition, TRP-2 (tyrosinase-related protein 2) can be produced by converting DOPA chrome into 5,6-dihydroxyindole-2-carboxylic acid, TRP-1 tyrosinase-related protein 1 catalyzes the oxidation reaction to indole-5,6-quinone-2-carboxylic acid and inhibits tyrosinase (eu) production in eumelanin synthesis tyrosinase) and TRP-1 and 2 are involved. In addition, the microphthalmia-associated transcription factor (MITF), well known as a regulator of melanin formation, is a transcription factor with a helix-loop-helix-leucine zipper structure. Is known to regulate the process of blackening and the proliferation and survival of cells. Melanocyte stimulating hormone (α-MSH), adrenocorticotropic hormone (PGE2), and prostaglandin E2 (melanocyte stimulating hormone), which are involved in melanin biosynthesis, have been reported to regulate melanin synthesis through cAMP.
현재 합성 항산화제로 사용되는 코직산, 비타민 유도체, 알부틴, BHT(dibutylated hydroxytoluene) 등은 가격도 저렴하고 항산화 활성으로 인하여 우수한 미백 효과를 나타내지만, 과다 사용하게 되면 질병을 유발하는 등 안전성에 문제점이 있는 것으로 보고되고 있어 사용량을 규제하고 있다. 현재 국내외적으로 천연물로부터 기능성 성분의 소재를 발굴하기 위한 연구가 활발히 진행되고 있다.Currently, kojic acid, vitamin derivatives, arbutin and dibutylated hydroxytoluene (BHT), which are used as synthetic antioxidants, are inexpensive and exhibit excellent whitening effect due to their antioxidative activity. However, It is reported and regulates usage. Currently, studies are being actively carried out to find functional materials from natural products both domestically and externally.
백전은 박주가리과 식물인 민백미꽃(Cynanchum ascyrifolium)의 뿌리를 말린 것으로, 우리나라 각처의 산과 들에서 자라는 다년생 초본이다. 생육환경은 반그늘이고 물 빠짐이 좋은 비옥한 토양에서 자란다. 키는 30~60㎝이고, 잎은 길이가 8~15㎝, 폭은 4~8㎝로 양면에 잔털이 있으며 타원형이고 마주난다. 꽃은 백색이고 지름이 약 2㎝로 원줄기 끝과 윗부분의 잎겨드랑이에서 나오고 펼쳐지듯 달리며, 꽃 안에 들어 있는 백색은 삼각형이고 5개로 갈라진다. 열매는 8~9월경에 달리고 종자는 익으면 흰색털이 달려있으며, 관상용으로 쓰이며, 뿌리는 약용으로 쓰인다. The white flour is the Cynanchum ascyrifolium ) is a perennial herb that grows in the mountains and fields of each country. The growing environment grows in a fertile soil which is semi-shiny and watery. The leaves are 30 ~ 60㎝ long, 8 ~ 15㎝ long, 4 ~ 8㎝ wide, with fine hairs on both sides and facing oval. The flower is white and the diameter is about 2㎝. It comes out from the tip of the main stem and the axilla of the upper part. It spreads as if spreading. The white inside the flower is triangular and divided into 5 pieces. Fruits run around August to September, seeds have white hairs on ripe, are used for ornamental purposes, and roots are used for medicinal purposes.
한편, 한국등록특허 제1047588호에는 백미 추출물 및 이로부터 분리된 신규 프레그난계 화합물을 유효성분으로 포함하는 미백용 조성물에 대해 개시하고 있으며, 한국공개특허 제2013-0134976호에는 백미 추출물을 함유하는 피부노화 방지를 위한 화장료 조성물에 대해 개시하고 있다. 하지만, 본 발명의 백전 추출물을 유효성분으로 함유하는 미백용 조성물에 대해 아직까지 개시된 바가 없다.On the other hand, Korean Patent No. 1047588 discloses a whitening composition comprising a white rice extract and a novel pregranate compound isolated therefrom as an active ingredient. In Korean Patent Laid-Open Publication No. 2013-0134976, a white rice extract And a cosmetic composition for preventing skin aging. However, the whitening composition containing the present white burn extract as an active ingredient has not yet been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명에서는 백전 추출물이 항산화 활성을 나타내며, 이를 멜라노마 세포(B16-F10 mouse melanoma cell)에 처리하였을 때, 멜라닌의 생성을 효과적으로 억제할 뿐만 아니라, 기존 미백제인 알부틴보다 티로시나아제의 활성을 저해하는 효과가 우수한 것을 확인함으로써, 본 발명을 완성하였다.SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned needs, and it is an object of the present invention to provide an antioxidative activity of the white spot extract, which inhibits the production of melanin effectively when treated with melanoma cells (B16-F10 mouse melanoma cells) , Confirming that the effect of inhibiting the activity of tyrosinase is superior to arbutin, which is a conventional whitening agent, to complete the present invention.
상기 과제를 해결하기 위하여, 본 발명은 백전 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물을 제공한다.In order to solve the above-mentioned problems, the present invention provides a cosmetic composition for skin whitening comprising a white flake extract as an active ingredient.
또한, 본 발명은 백전 추출물을 유효성분으로 함유하는 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학조성물을 제공한다.The present invention also provides a pharmaceutical composition for preventing or treating a melanin pigment hyperpigmentation disorder, which comprises a white flake extract as an active ingredient.
또한, 본 발명은 백전 추출물을 유효성분으로 함유하는 멜라닌 색소 과다 침착 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for preventing or ameliorating hyperpigmentation of melanin pigment, which comprises a white flake extract as an active ingredient.
본 발명의 백전 추출물은 항산화 활성을 나타내며, 멜라닌의 생성을 효과적으로 억제할 뿐만 아니라, 기존 미백제인 알부틴보다 티로시나아제의 저해활성이 우수하므로, 피부 미백을 위한 기능성 화장품 및 피부 색소 침착 질환을 예방 또는 개선시킬 수 있는 건강기능식품 또는 피부 색소 침착 질환의 치료제로서 유용하게 사용할 수 있다.The present white star extract exhibits an antioxidative activity and not only effectively inhibits the production of melanin but also has an inhibitory activity of tyrosinase over arbutin, which is a conventional whitening agent, so that functional cosmetics for skin whitening and skin pigmentation diseases can be prevented or prevented Can be usefully used as a remedy for health functional foods or skin pigmentation diseases that can be improved.
도 1은 본 발명의 일 실시예에 따른 백전 추출물을 농도별로 B16F10 마우스 멜라노 세포에 처리하였을 때, 세포 생존율(cell viability)을 나타낸 것이다. CON은 DMEM 배지를 처리한 음성 대조군이다.
도 2는 본 발명의 일 실시예에 따른 α-MSH(α-melanocyte stimulating hormone) 및 백전 추출물을 농도별로 B16F10 마우스 멜라노 세포에 처리하였을 때, B16F10 마우스 멜라노 세포 내 멜라닌의 함량 및 티로시나아제의 활성을 측정한 결과를 나타낸 것이다. α-MSH은 멜라닌 생성 유도물질이며, AR은 알부틴(arbutin)으로 양성 대조군이다.FIG. 1 is a graph showing cell viability of B16F10 mouse melanocytes treated with white flake extract according to an embodiment of the present invention. CON is a negative control group treated with DMEM medium.
FIG. 2 is a graph showing the activity of melanocytes in melanocytes of B16F10 mouse melanocytes and tyrosinase activity of B16F10 mouse melanocytes treated with α-MSH (α-melanocyte stimulating hormone) As shown in FIG. α-MSH is a melanogenesis inducer, and AR is a positive control for arbutin.
본 발명의 목적을 달성하기 위하여, 본 발명은 백전 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물을 제공한다.In order to accomplish the object of the present invention, the present invention provides a cosmetic composition for skin whitening comprising a white flake extract as an active ingredient.
본 발명의 일 구현 예에 따른 화장료 조성물에서, 상기 백전 추출물은 물, 탄소수 1 내지 4의 저급 알코올 및 이들의 혼합용매로 구성되는 군으로부터 선택되는 용매, 바람직하게는 에탄올을 용매로 이용하여 추출한 것이다.In the cosmetic composition according to an embodiment of the present invention, the white burn extract is extracted with a solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof, preferably ethanol as a solvent .
예를 들면, 상기 백전 추출물은For example,
1) 백전을 분쇄하여 분말을 제조하는 단계;1) milling the white powder to produce a powder;
2) 상기 백전 분말 중량 대비 5~15배의 부피부로 에탄올을 첨가하고 실온에서 5~15시간 동안 중탕하여 추출하는 단계; 및2) adding 5 to 15 times by volume of ethanol to the white powder and extracting it by hot water bath at room temperature for 5 to 15 hours; And
3) 상기 단계 2)에서 중탕하여 획득한 백전 추출물을 여과 및 농축한 후 동결건조하는 단계;를 포함하여 제조한 것일 수 있으며, 3) filtration and concentration of the white prickly extract obtained by stirring in step 2), followed by lyophilization,
바람직하게는, 1) 백전을 분쇄하여 분말을 제조하는 단계;Preferably, 1) milling the white powder to produce a powder;
2) 상기 백전 분말 중량 대비 10배의 부피부로 70% 에탄올을 첨가하고 실온에서 10시간 동안 중탕하여 추출하는 단계; 및2) adding 70% ethanol to the whiteness of 10 times the weight of the white powder, and extracting it by hot water bath at room temperature for 10 hours; And
3) 상기 단계 2)에서 중탕하여 획득한 백전 추출물을 여과 및 농축한 후 동결건조하는 단계;를 포함하여 제조한 것일 수 있으나, 이에 제한되지 않는다.3) filtration and concentration of the whitergast extract obtained by the step 2), followed by lyophilization, but the present invention is not limited thereto.
또한, 상기 화장료 조성물은 멜라닌(melanin)의 생성 또는 티로시나아제(tyrosinase)의 활성을 억제할 수 있으나, 이에 제한되지 않는다.In addition, the cosmetic composition may inhibit the production of melanin or the activity of tyrosinase, but is not limited thereto.
한편, 미백 효과란, 자외선 노출, 호르몬 밸런스의 변화, 유전적 프로그램 등의 각종 요인에 의해 발생하는 거뭇한 피부나 기미, 주근깨, 다크서클을 개선 또는 방지하는 효과, 피부를 투명감 있는 아름다운 것으로 하는, 혹은 투명감 있는 아름다운 피부를 유지하는 효과, 피부의 칙칙함을 경감하여 윤기ㆍ팽팽함을 증가시키는 효과 등을 의도하고 있다. 일반적으로, 거뭇한 피부나 기미, 주근깨, 다크서클은 자외선에 의한 자극이나 호르몬 밸런스의 변화 등에 의해 멜라노사이트(melanocyte)가 자극되고, 그래서 생합성된 멜라닌 색소가 피부에 침착하여 발생한다고 알려져 있다. 따라서, 멜라닌의 생성을 억제할 수 있다면, 거뭇한 피부나 기미, 주근깨, 다크서클을 예방ㆍ개선하는 것이 가능하다. On the other hand, the whitening effect refers to an effect to improve or prevent glaring skin, spots, freckles, and dark circles caused by various factors such as exposure to ultraviolet rays, change in hormone balance, genetic program, Or an effect of maintaining a beautiful skin with a sense of transparency and an effect of reducing the dullness of the skin to increase gloss and tautness. In general, it is known that the skin, spots, freckles, and dark circles of the skin, stamens, freckles and dark circles are stimulated by melanocytes due to stimulation by ultraviolet rays or changes in hormone balance, and melanin pigment is deposited on the skin. Therefore, if the production of melanin can be inhibited, it is possible to prevent or improve gross skin, spots, freckles and dark circles.
또한, 상기 피부 미백용 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 이루어지는 군으로부터 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않는다. 보다 구체적으로는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이, 파우더, 팩트, 립글로즈, 립스틱, 섀도우 등의 제형으로 제조될 수 있다. 이들 각 제형으로 이루어진 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다.The cosmetic composition for skin whitening may be a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleansing oil, a powder foundation, an emulsion foundation, a wax foundation and a spray , But the present invention is not limited thereto. More specifically, it is formulated into formulations such as soft lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, fact, lip gloss, lipstick and shadow . The cosmetic composition comprising each of these formulations may contain various bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.
본 발명의 화장료 조성물은 유효성분 이외에 추가로 동일 또는 유사한 기능을 나타내는 피부 미백 활성 성분을 1종 이상 함유할 수 있다. 피부 미백 활성 성분으로는 코지산 및 이의 유도체, 알부틴, 아스코르브산 및 이의 유도체, 하이드로퀴논 및 이의 유도체, 레조르시놀, 사이클로알카논, 메틸렌디옥시페닐 알칸올, 2,7-디니트로인다졸 또는 덩굴귤 추출물, 쌀 추출물, 감초 추출물과 같은 식물 추출물 등이 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may contain, in addition to the active ingredient, at least one skin whitening active ingredient exhibiting the same or similar functions. Skin whitening active ingredients include kojic acid and its derivatives, arbutin, ascorbic acid and its derivatives, hydroquinone and its derivatives, resorcinol, cycloalkanone, methylenedioxyphenylalkanol, 2,7-dinitroindazole or Plant extracts such as mandarin orange extract, rice extract, licorice extract, and the like, but are not limited thereto.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판-부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, Propellants such as carbon, propane-butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 아세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is an interfacial-active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative or ethoxylated glycerol fatty acid ester.
본 발명의 화장료 조성물은 형광물질, 살진균제, 굴수성 유발물질, 보습제, 방향제, 방향제 담체, 단백질, 용해화제, 당 유도체, 일광차단제, 비타민, 식물 추출물 등을 포함하는 부형제를 추가로 함유할 수 있다.The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a hygroscopic substance, a moisturizer, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen, a vitamin, .
또한, 본 발명은 백전 추출물을 유효성분으로 함유하는 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학조성물을 제공한다.The present invention also provides a pharmaceutical composition for preventing or treating a melanin pigment hyperpigmentation disorder, which comprises a white flake extract as an active ingredient.
본 명세서에서 사용되는 용어 "멜라닌 색소 과다 침착(hyperpigmentation)"은 피부 또는 손·발톱의 특정 부위에서 멜라닌의 과도한 증가에 의해 다른 부위에 비해 검게 또는 어둡게 되는 것을 의미한다. 상기 멜라닌 색소 과다침착 질환은 주근깨, 노인성 반점, 간반, 기미, 갈색 또는 흑점, 일광 색소반, 푸른흑피증(cyanic melasma), 약물 사용 후의 과다색소침착, 임신성 갈색반(gravidic chloasma), 또는 찰상 및 화상을 비롯한 상처 또는 피부염으로 인한 염증 후 과다 색소 침착 등을 포함하나 이에 한정되지 않는다.The term " melanin pigment hyperpigmentation " as used herein means darker or darker than other areas due to excessive increase of melanin in specific areas of skin or hands and toenails. The melanin pigment hyperpigmentation disorder can be selected from the group consisting of freckles, senile spots, liver, spots, brown or black spots, daylight pigmentation, cyanic melasma, hyperpigmentation after drug use, gravidic chloasma, Post-inflammatory hyperpigmentation due to burns or dermatitis including burns, and the like.
본 발명의 약학조성물은 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있으며, 이러한 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약학적으로 허용되는 담체 및 제제는 레밍턴의 약학적 과학(Remington's Pharmaceutical Sciences, 19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to the active ingredient. Such a carrier is usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, Calcium carbonate, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals Oils, and the like, but are not limited thereto. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.
본 발명에 따른 약학조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. The appropriate dosage of the pharmaceutical composition according to the present invention may vary depending on such factors as the formulation method, the administration method, the patient's age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, .
본 발명의 약학조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구 투여의 경우, 피부에 국소적으로 도포, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다. 본 발명의 약학조성물이 멜라닌 색소 과다 침착 질환을 치료 또는 예방을 위해 적용되는 점을 감안하면, 피부에 국소적으로 도포되어 이루어지는 것이 바람직하다.The pharmaceutical composition of the present invention may be administered orally or parenterally. In the case of parenteral administration, the composition may be administered topically to the skin, intravenously, subcutaneously, intramuscularly, intraperitoneally, or transdermally. In view of the fact that the pharmaceutical composition of the present invention is applied for the treatment or prevention of a melanin pigment hyperpigmentation disease, it is preferable that the composition is topically applied to the skin.
본 발명의 조성물에 포함되는 유효성분의 농도는 치료 목적, 환자의 상태, 필요기간 등을 고려하여 결정할 수 있으며 특정 범위의 농도로 한정되지 않는다.The concentration of the active ingredient contained in the composition of the present invention can be determined in consideration of the purpose of treatment, the condition of the patient, the period of time required, and the like, and is not limited to a specific range of concentration.
본 발명의 약학조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 주사제, 크림, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 중에서 선택된 어느 하나의 제형으로 제조될 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be manufactured in a unit dosage form by formulating it using a pharmaceutically acceptable carrier or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs Into a capacity container. The formulations may be formulated into any one of the formulations selected from injectables, creams, patches, sprays, ointments, alerts, lotions, liniments, pastes and cataplasms, and may additionally contain dispersing or stabilizing agents have.
또한, 본 발명은 백전 추출물을 유효성분으로 함유하는 멜라닌 색소 과다 침착 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for preventing or ameliorating hyperpigmentation of melanin pigment, which comprises a white flake extract as an active ingredient.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취한 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient can be suitably used depending on its use purpose (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in case of long-term ingestion for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다.
In addition to the above health functional food composition, it is also possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
재료 및 방법Materials and methods
1. One. 백전Whiteness 추출물의 제조 및 추출수율 측정 Preparation of extract and measurement of extraction yield
본 발명의 백전 추출물은 백전 분말 중량 대비 10배의 70% 에탄올을 첨가한 후, 실온에서 10시간 동안 중탕하면서 추출하였으며, 추출수율을 측정하기 위해 상기 백전 추출물을 여과 및 농축한 후 동결건조하여 건물 중량을 구한 후, 추출에 사용한 원료 건물량에 대한 백분율로 계산하였다.
The white flake extract of the present invention was prepared by adding 10 times 70% ethanol to the weight of the white powder, and then extracting the mixture while stirring at room temperature for 10 hours. To measure the extraction yield, the white flake extract was filtered and concentrated, After the weight was determined, it was calculated as a percentage of the dry matter amount used for the extraction.
2. 총 폴리페놀 함량 측정2. Total polyphenol content measurement
총 폴리페놀의 함량은 거트핑거(Gutfiger T., 1981, J Am Oil Chem Soc, Vol.58, 966-968)의 방법을 변형하여 측정하였다. 본 발명의 백전 추출물 희석액 100㎕에 100㎕의 폴린-시오칼토반응(Folin-Ciocalteau reation) 용액을 첨가하고 3분간 정치한 후 1㎖의 0.7M Na2CO3 용액을 첨가하여 혼합하였다. 이 혼합액을 1시간 동안 반응시킨 후 분광광도계를 사용하여 750nm에서 흡광도를 측정하였다. 백전 추출물의 총 폴리페놀 함량은 표준물질인 탄닌산(tannic acid)을 기준으로 표준곡선을 작성하여 계산하였다.
The total polyphenol content was determined by modifying the method of Gutfiger T., 1981, J Am Oil Chem Soc, Vol. 58, 966-968. 100 쨉 l of Folin-Ciocalteau reaction was added to 100 쨉 l of the present invention, and the mixture was allowed to stand for 3 minutes. Then, 1 ml of 0.7 M Na 2 CO 3 solution was added and mixed. After the mixture was reacted for 1 hour, the absorbance was measured at 750 nm using a spectrophotometer. The total polyphenol content of the scutellaria baicalensis extract was calculated by preparing a standard curve based on tannic acid, a standard substance.
3. 3. DPPHDPPH 라디칼 소거활성 측정 Measurement of radical scavenging activity
DPPH(1,1-diphenyl-2-picryl-hydrazyl) 라디칼 소거 활성 측정은 블로이즈(Blois M.S., Nature, 1958, 26, 1199-1200)의 방법을 변형하여 측정하였다. 100㎕의 백전 추출물에 0.2mM DPPH 용액 50㎕를 첨가하고 10분 동안 반응시킨 후 517nm에서 흡광도를 측정하였다. DPPH 라디칼 소거능은 백전 추출물의 처리구 및 무처리구의 흡광도 감소율로 계산하였고, DPPH 라디칼 소거활성이 50% 감소하는데 필요한 백전 추출물의 농도인 RC50 값으로 나타내었다.
Measurement of DPPH (1,1-diphenyl-2-picryl-hydrazyl) radical scavenging activity was measured by modifying the method of Blois MS, Nature, 1958, 26, 1199-1200. 50 μl of a 0.2 mM DPPH solution was added to 100 μl of the white flake extract, and reacted for 10 minutes, and the absorbance was measured at 517 nm. The DPPH radical scavenging activity was calculated by the absorbance reduction rate of the treated and untreated control of the whiteness extract, and the RC50 value, which is the concentration of the whiteness extract required for the reduction of the DPPH radical scavenging activity by 50%.
4. 4. ABTSABTS 라디칼 소거 활성 측정 Measurement of radical scavenging activity
ABTS(2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 라디칼 소거 활성 측정은 블로이즈(Blois M.S., Nature, 1958, 26, 1199-1200)의 방법을 변형하여 측정하였다. 7mM ABTS 및 2.45mM K2S2O8(potassium persulfate)을 혼합하여 1일 동안 암소에 방치하여 ABTS·+를 형성시킨 후, 상기 혼합용액을 734nm에서 0.7~0.9가 되도록 몰 흡광계수를 이용하여 증류수로 희석하였다. 50㎕의 백전 추출물에 희석된 ABTS·+ 용액을 100㎕을 첨가하여 5분 후에 흡광도의 변화를 측정하였다. ABTS 라디칼 소거능은 백전 추출물의 처리구 및 무처리구의 흡광도 감소율로 계산하였고, ABTS 라디칼 소거활성이 50% 감소하는데 필요한 백전 추출물의 농도인 RC50 값으로 나타내었다.
Measurement of ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) radical scavenging activity was measured by modifying the method of Blois MS, Nature, 1958, 26, 1199-1200. ABTS and 2.45 mM K 2 S 2 O 8 (potassium persulfate) were mixed and allowed to stand in a dark place for 1 day to form ABTS · + . Then, the mixed solution was stirred at 734 nm for 0.7 to 0.9 using molar extinction coefficient diluted with. by the ABTS · + solution diluted in baekjeon extract of 50
5. 세포생존율(cell viability) 측정5. Measurement of cell viability
백전 추출물의 세포독성에 미치는 영향을 확인하기 위해, MTT(3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 분석을 실시하여 세포생존율을 측정하였다. B16F10 마우스 멜라노마 세포를 100㎕의 DMEM 배지가 담긴 96-웰 플레이트에 1일 동안 배양한 후, 다양한 농도(25, 50 및 100㎍/㎖)의 백전 추출물을 처리하여 24시간 배양하였다. 그런 다음에, 각 웰에 5mg/㎖의 MTT 용액을 10㎕씩 분주한 후 3시간 동안 배양하면서 환원반응을 유도하였으며, 100㎕의 DMSO(dimethyl sulfoxide) 용액을 첨가하여 보라색의 포르마잔(formazan) 결정을 완전히 용해시켰다. 분광광도계를 이용하여 570nm에서 흡광도를 측정하였으며, 세포생존율은 세포만 배양한 무처리구의 생존율 100%를 기준으로 본 발명의 백전 추출물 처리구의 상대적인 세포생존율을 계산하였다.
The cell viability was determined by MTT assay (3- (4,5-dimeth-ylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) analysis. B16F10 mouse melanoma cells were cultured in a 96-well plate containing 100 占 퐇 of DMEM medium for 1 day and then subjected to treatment with various concentrations (25, 50 and 100 占 퐂 / ml) of the white extract for 24 hours. Then, 10 μl of 5 mg / ml MTT solution was added to each well, followed by incubation for 3 hours to induce a reduction reaction. 100 μl of DMSO (dimethyl sulfoxide) solution was added to form purple formazan, The crystals were completely dissolved. Absorbance was measured at 570 nm using a spectrophotometer. The cell viability was calculated based on the survival rate of the untreated control cells cultured in the cells alone.
6. 멜라닌(Melanin)의 생합성 및 티로시나아제(6. Biosynthesis of melanin and tyrosinase ( tyrosinasetyrosinase )의 활성 측정) Activity measurement
B16F10 마우스 멜라노마 세포를 12-웰 플레이트에 1×105 cells/㎖이 되도록 접종하여 24시간 동안 배양한 후, 각 웰에 α-MSH(melanocyte-stimulating hormone)를 처리하여 멜라닌 생성을 유도한 뒤 알부틴(arbutin 100㎍/㎖) 및 농도별로 제조한 백전 추출물(25, 50 및 100㎍/㎖)을 각각 48시간 동안 처리하였다. 처리한 후 PBS(phosphate buffered saline)로 2회 세척한 후 원심분리하여 세포 침전물을 만들었으며, 10% DMSO(dimethyl sulfoxide)가 첨가된 1N NaOH 용액 200㎕를 첨가하고 60℃에서 1시간 동안 용해시켰으며 405nm에서 흡광도를 측정하였다. 티로시나아제(Tyrosinase)의 활성은 0.1M 소듐 포스페이트 버퍼(sodium phosphate buffer, pH 6.8) 1㎖에 10mM L-DOPA(L-3,4-dihydroxypheny-lalanine)를 녹인 160㎕의 기질액 및 40㎕의 백전 추출물의 혼합액을 37℃에서 1시간 동안 반응시켜 반응액 중에 생성된 도파 크롬(DOPA chrome)을 475nm에서 측정하였다. 티로시나아제의 저해 활성은 백전 추출물의 처리구 및 무처리구의 흡광도 감소율로 나타내었다.
B16F10 mouse melanoma cells were inoculated on a 12-well plate at a density of 1 x 10 5 cells / ml and cultured for 24 hours. Melanocyte production was induced by treating α-MSH (melanocyte-stimulating hormone) Arbutin (100 μg / ml) and the white extracts (25, 50 and 100 μg / ml) prepared for each concentration were treated for 48 hours. After washing with PBS (phosphate buffered saline), the cells were centrifuged to make a cell suspension. 200 μl of 1 N NaOH solution containing 10% DMSO (dimethyl sulfoxide) was added and dissolved at 60 ° C for 1 hour And absorbance was measured at 405 nm. The activity of tyrosinase was determined by adding 160 μl of substrate solution and 10 μl of L-DOPA (L-DOPA) dissolved in 1 ml of 0.1 M sodium phosphate buffer (pH 6.8) Was reacted at 37 ° C for 1 hour to measure Dopamine chrome (DOPA chrome) produced in the reaction solution at 475 nm. The inhibitory activity of tyrosinase was expressed by the absorbance reduction rate of the treatment of the white spot extract and the untreated area.
실시예Example 1. One. 백전Whiteness 추출물의 추출수율, 총 폴리페놀 The extraction yield of the extract, total polyphenol 함량 및 항산화Content and Antioxidant 활성 측정 Active measurement
산업적 측면에서 볼 때, 천연물의 추출 수율은 부가 가치적 측면에서 매우 중요한 요소로 작용한다. 따라서 본 실시예 1에서는 백전 추출물의 추출 수율을 측정하였다. 그 결과, 하기 표 1에 개시한 바와 같이 추출수율은 15.14%로 측정되었다.From the industrial point of view, the extraction yield of natural products is very important in terms of value added. Therefore, in Example 1, the extraction yield of the white prick extract was measured. As a result, the extraction yield was 15.14% as shown in Table 1 below.
폴리페놀계 물질들은 식물체에 특수한 색깔을 부여하고 산화환원반응에서 기질로 작용하며, 한 분자 내에 2개 이상의 OH(phenolic hydroxy)기를 가진 방향족 화합물이다. 이의 주성분인 플라보노이드 및 탄닌은 충치 예방, 고혈압 억제, 항에이즈, 항산화, 항암 등의 다양한 생리활성을 가진다. 플라보노이드는 페놀 화합물 중에서 자연적으로 생성되는 가장 큰 그룹의 하나로서 안토시아닌(anthocyanin), 칼콘(chalcone), 오론(aurone), 플라본(flavone), 플라보놀(flavonol) 및 이들의 유도체 등으로 나눌 수 있다. 따라서, 백전 추출물의 총 페놀 화합물 함량을 측정한 결과, 21.72mg/g으로 측정되었으며, 항산화 활성을 측정한 결과, 100㎍/㎖의 백전 추출물에서 ABTS 라디칼 소거능이 13.31%로 측정되었으며, DPPH 라디칼 소거능은 나타내지 않았다.Polyphenolic materials are aromatic compounds that give plants specific colors and act as substrates in redox reactions, and have two or more OH (phenolic hydroxy) groups in a molecule. Its principal components, flavonoids and tannins, have various physiological activities such as tooth decay prevention, hypertension inhibition, anti-AIDS, antioxidant, and anti-cancer. Flavonoids are one of the largest naturally occurring groups of phenolic compounds and can be divided into anthocyanin, chalcone, aurone, flavone, flavonol and their derivatives. As a result, the total phenolic compound content of the white flake extract was measured to be 21.72 mg / g. The antioxidative activity of the extract was found to be 13.31% for the ABTS radical scavenging activity in 100 μg / Lt; / RTI >
(mg/Extract 1g)Total phenol content
(mg / Extract 1g)
실시예Example 2. 본 발명의 2. The present invention 백전Whiteness 추출물 처리에 따른 세포생존율(cell viability) 분석 Analysis of cell viability by extract treatment
B16F10 마우스 멜라노마 세포에서 백전 추출물의 세포 독성을 조사하기 위해, 25, 50 및 100㎍/㎖의 백전 추출물을 24시간 처리한 후 MTT 분석을 실시하였다. 그 결과, 도 1에 개시한 바와 같이 DMEM 배지만을 처리한 대조군과 비교하였을 때, 백전 추출물의 모든 농도에서 세포의 생육 저해가 나타나지 않았으며, 대부분의 세포생존율이 약 100% 이상으로 백전 추출물이 세포독성이 없는 것으로 확인되었다. 따라서 하기 실시예 3에서는 세포독성이 나타나지 않는 25, 50 및 100㎍/㎖의 백전 추출물을 세포에 처리하여 미백효과를 검증하였다.
In order to investigate the cytotoxicity of Bacillus thuringiensis extracts on B16F10 mouse melanoma cells, 25, 50 and 100 μg / ml of Bacillus sp. Extracts were treated for 24 hours before MTT analysis. As a result, as shown in Fig. 1, when compared with the control group treated with DMEM, the inhibition of cell growth was not observed at all concentrations of the extract, and the cell survival rate was about 100% It was confirmed that there is no toxicity. Therefore, in Example 3 below, the whitening effect of 25, 50 and 100 μg / ml of the whiteness extract, which does not exhibit cytotoxicity, was tested on the cells.
실시예Example 3. 본 발명의 3. The 백전Whiteness 추출물 처리에 따른 멜라닌(melanin)의 생성 및 티로시나아제(tyrosinase)의 활성 저해효과 Production of melanin and inhibition of tyrosinase activity by extract treatment
멜라닌의 생합성은 아미노산의 일종인 티로신(tyrosin)을 전구물질로 하여,도파(DOPA), 도파 퀴논(DOPA quinone) 및 인돌-5,6-디히드로퀴논(indole-5,6-dihydroquinone)을 거쳐 인돌-5,6-디히드로퀴논의 중합체인 멜라닌으로 생합성 된다. 멜라닌은 멜라노사이트(melanocyte) 내에서 생성되며, 멜라노솜(melanosome)이라는 과립 형태로 표피와 진피의 경계부로 이동하여 침착된다. 멜라닌은 검은 피부의 직접적인 원인이 될 뿐만 아니라, 기미, 주근깨의 형성을 촉진하는 등 피부 미용 측면에서 심각한 문제를 일으킨다. 또한 과잉 생산된 멜라닌은 피부노화 및 피부암을 유발하는 원인이 되는 것으로 밝혀졌다. 따라서, 본 발명의 백전 추출물 처리에 따른 멜라닌(melanin)의 함량 및 티로시나아제(tyrosinase)의 활성을 측정한 결과, 도 2에 개시한 바와 같이 α-MSH를 처리하여 멜라닌 생성을 유도한 뒤 본 발명의 백전 추출물을 처리하였을 때, 멜라닌의 생성량이 감소하였으며 특히 100㎍/㎖의 백전 추출물을 처리한 경우, α-MSH 처리 대비 약 40%의 멜라닌의 함량을 감소시켰다. 또한, 티로시나아제(tyrosinase)의 활성도 마찬가지로 백전 추출물을 처리한 결과, 티로시나아제의 활성을 저해시켰으며, 특히 100㎍/㎖의 백전 추출물을 처리한 경우, 약 70%의 티로시나아제의 활성을 감소시켰으며 양성 대조군인 알부틴(arbutin)보다 더 우수한 저해효과를 나타내었다.The biosynthesis of melanin is carried out by using tyrosin, which is a kind of amino acid, as a precursor, through DOPA, DOPA quinone and indole-5,6-dihydroquinone, -5,6-dihydroquinone. ≪ / RTI > Melanin is produced in the melanocyte and is transferred to the epidermis and dermis boundary in the form of granules called melanosomes. Melanin is not only a direct cause of dark skin, but also causes serious problems in terms of skin beauty, such as promoting the formation of spots and freckles. In addition, over-producing melanin has been found to cause skin aging and skin cancer. Therefore, as a result of measuring the content of melanin and the activity of tyrosinase according to the present invention, the α-MSH was treated to induce melanin production as shown in FIG. 2, When the extract of the present invention was treated, the amount of melanin was decreased. In particular, when 100 μg / ml of the extract was treated, the content of melanin was reduced by about 40% compared with the α-MSH treatment. In addition, the activity of tyrosinase similarly inhibited the activity of tyrosinase as a result of treatment with the extract of Vaccinia. Especially, when 100 μg / ml of Vaccine extract was treated, the activity of tyrosinase of about 70% And showed better inhibitory effect than the positive control group arbutin.
Claims (8)
1) 백전을 분쇄하여 분말을 제조하는 단계;
2) 상기 백전 분말 중량 대비 5~15배의 부피부로 에탄올을 첨가하고 실온에서 5~15시간 동안 중탕하여 추출하는 단계; 및
3) 상기 단계 2)에서 중탕하여 획득한 백전 추출물을 여과 및 농축한 후 동결건조하는 단계;를 포함하여 제조한 것을 특징으로 하는 피부 미백용 화장료 조성물.[Claim 2] The method according to claim 1,
1) milling the white powder to produce a powder;
2) adding 5 to 15 times by volume of ethanol to the white powder and extracting it by hot water bath at room temperature for 5 to 15 hours; And
3) filtering and concentrating the whitewash extract obtained by the step 2) and freeze-drying the cosmetic composition for skin whitening.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160067484A KR101823928B1 (en) | 2016-05-31 | 2016-05-31 | Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160067484A KR101823928B1 (en) | 2016-05-31 | 2016-05-31 | Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170135485A true KR20170135485A (en) | 2017-12-08 |
KR101823928B1 KR101823928B1 (en) | 2018-01-31 |
Family
ID=60919652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160067484A KR101823928B1 (en) | 2016-05-31 | 2016-05-31 | Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101823928B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100797366B1 (en) | 2000-10-12 | 2008-01-22 | 주식회사 엘지생활건강 | Cosmetic composition containing Liquidambar taiwaniana Hance extracts and Cynanchum atratum Bunge extracts |
KR101047588B1 (en) | 2008-07-29 | 2011-07-08 | 충북대학교 산학협력단 | Whitening composition comprising white rice extract and novel pregnan compound isolated therefrom as active ingredient |
-
2016
- 2016-05-31 KR KR1020160067484A patent/KR101823928B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101823928B1 (en) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR101743200B1 (en) | Composition for skin whitening comprising fraction of fruit extract of Sageretia thea as effective component | |
KR101453258B1 (en) | Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty | |
KR101203504B1 (en) | Composition for Wrinkle-Care or Skin Whitening Containing Fermentation Liquor of Extract from Stewartia koreana | |
KR101943976B1 (en) | Composition for skin whitening comprising Capsicum annuum seed extract as effective component | |
KR20100071476A (en) | Composition for whitening containing extract of annona muricata as an active ingredient | |
KR101863895B1 (en) | Composition for skin whitening comprising Stachys sieboldii extract fermented using Hericium erinaceum mycelium as effective component | |
KR101832169B1 (en) | Composition for skin whitening comprising extract of Picrasma quassioides as effective component | |
KR20130023606A (en) | Composition for whitening of the skin comprising an extract of sophora japonica l., leguminosae | |
KR20190077156A (en) | Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component | |
KR20190100791A (en) | Composition for skin whitening comprising extract of Eriobotrya japonica leaf | |
KR101551106B1 (en) | A composition comprising the extract of Paspalum thunbergii Kunth | |
KR101823928B1 (en) | Composition for skin whitening comprising extract of Cynanchum ascyrifolium as effective component | |
KR102035188B1 (en) | Composition for skin whitening comprising Cacalia firma extract as effective component | |
KR102264157B1 (en) | Cosmetic composition for improving skin whitening and cleansing comprising fermented liquor of sheath of bamboo shoot as effective component | |
KR102016994B1 (en) | Pepper leaf extreact with improved skin whitening effect and manufacturing method thereof | |
KR20130136753A (en) | Cosmetic composition comprising cercis chinensis or reynoutria japonica for. elata extract for skin whitening | |
KR102034178B1 (en) | Plasma-treated pepper leaf extreact with improved skin whitening effect and manufacturing method thereof | |
KR101971254B1 (en) | Composition for skin whitening comprising Pavetta indica extract as effective component | |
KR20100042086A (en) | Composition for whitening containing extract of cortex cinnamomi cassiae | |
KR101858118B1 (en) | Composition for skin whitening comprising fermented Geomgangsong as effective component | |
KR102240026B1 (en) | Composition for skin whitening comprising Rhododendron schippenbachii root extract as effective component | |
KR101592117B1 (en) | A composition comprising the extract of Geranuium eriostemon | |
KR101931269B1 (en) | Composition for skin whitening comprising extract of roasted Alpinia katsumadai semen as effective component | |
KR102215699B1 (en) | Antioxidant and whitening composition containing Thymus quinquecostatus oil as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant |